Erlonat 100mg Tablet
Rx RequiredSalt Composition: Erlotinib
Expiry Date: 01/2028
Buy at $71.94
Inclusive of all taxes
30 Tablet in Bottle
About The Product
Lung Cancer, Metastatic Cancer
Erlonat 100mg tablet is an anticancer drug prescribed to patients suffering from advanced non-small cell lung cancer and pancreatic cancer. This tablet has a salt constituent called 'Erlotinib,' which belongs to the drug class of 'kinase inhibitors. It stops the working of the abnormal protein that leads to cancerous growth.
Erlonat is not recommended for children below 18 years of age. If you are taking any antacid medications, maintain a gap of 2-3 hours after taking Erlonat 100mg Tablet.
Side Effects
Side effects are unwanted symptoms that can occur from any medical treatment. Like other medications, the Erlonat 100mg Tablet can also have adverse effects on the body, most of which resolve without the need for medical attention.
Some common side effects include:
- Fever
- Rash
- Cough
- Fatigue
- Diarrhea
- Hair loss
- Vomiting
- Bone pain
- Constipation
- Muscles pain
- Appetite loss
- Abdominal pain
- Difficulty in breathing
- Infection in the mouth and stomach
Contact your doctor immediately if you experience any severe or unusual side effects.
How To Use
Erlonat 100mg tablet is a prescription-based anticancer drug that should be administered orally.
The doctor determines the dosage of this tablet based on your health condition.
It should be taken on an empty stomach, and it must not be chewed or crushed.
How It Works
Erlonat 100mg tablet contains its salt constituents known as Erlotinib, which belongs to the drug class of kinase inhibitors. Epidermal growth factor receptors (EGFR) are proteins that are found on lung cancer cells. These proteins receive signals and regulate the growth of cancer cells.
This drug binds to the chemical messenger and disturbs the cancer signaling pathway mediated by EGFR. This is how it blocks the growth and multiplication of the cancer cells.
Safety Advice
Missed Doses
- It is advised not to miss any scheduled dosage of Erlonat 100mg tablet.
- In case you miss a dose, consult your doctor immediately.
- Don't overdose to compensate for the missed one.
- Contact your doctor or any healthcare provider and seek medical attention immediately in such cases.
Quick Tips
- Inform your doctor immediately if you see blood in your stools after taking Erlonat 100mg Tablet.
- Taking Erlonat 100mg Tablet can make your skin sensitive. So wear high SPF sunscreen while going out or exposed to direct sun rays.
- Erlonat Tablet is not considered to be safe for pregnant and breastfeeding women, as it may pass through the mother and harm the baby.
- It is advised to use trusted methods of birth control and contraceptive pills to delay pregnancy while under treatment with Erlonat 100mg Tablet.
- Diarrhea is the most common side effect after taking Erlonat 100mg Tablet. So, drink plenty of water and fluid to keep your body hydrated.
- Do not take antacids medicine (Medicine lowers the stomach acid) with Erlonat 100mg Tablet, as it may interact with the tablet and can affect the action.
FAQs
Erlonat 100mg Tablet is considered to be safe for diabetic patients.
However, it is important to consult your doctor about doses before taking them.
Reference
1. Bareschino, M.
A., Schettino, C., Troiani, T., Martinelli, E., Morgillo, F., & Ciardiello, F. (2007).
Erlotinib in cancer treatment. Annals of oncology, 18, vi35-vi41 - https://pubmed.ncbi.nlm.nih.gov/17591829/ 2.
Abdelgalil, A. A., Al-Kahtani, H.
M., & Al-Jenoobi, F. I.
(2020). Erlotinib.
In Profiles of drug substances, excipients and related methodology (Vol. 45, pp.
93-117). Academic Press.
3. Tsao, M.
S., Sakurada, A., Cutz, J. C., Zhu, C.
Q., Kamel-Reid, S., Squire, J., ... & Shepherd, F. A.
(2005). Erlotinib in lung cancer—molecular and clinical predictors of outcome.
New England Journal of Medicine, 353(2), 133-144 - https://pubmed.ncbi.nlm.nih.gov/16014883/ 4. Steins, M., Thomas, M., & Geißler, M.
(2018). Erlotinib.
Small molecules in oncology, 1-17. 5.
Cohen, M. H., Johnson, J.
R., Chen, Y. F., Sridhara, R., & Pazdur, R.
(2005). FDA drug approval summary: erlotinib (Tarceva®) tablets.
The oncologist, 10(7), 461-466 - https://pubmed.ncbi.nlm.nih.gov/16079312/
Medical Disclaimer
Accurate, reviewed information to support informed healthcare decisions
Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.
The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.
This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.
Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.
.png&w=48&q=75 "Cart"){kind=small}
9655.png&w=48&q=75 "Home"){kind=small}
